PopVax's fridge-stable RNA vaccine enters Phase I trial in Australia, first two participants dosed
CatAstro_Piyush · x · 2026-10-10
On August 31, the first two participants were dosed with PopVax India's first fridge-stable RNA vaccine candidate in a Phase I clinical trial in Australia. The company says the vaccine was built end-to-end — from computational design to GMP manufacturing — at its RNA Foundry in Hyderabad, showcasing a small-team, vertically integrated approach to RNA drug development.
Related event: PopVax Begins Phase I Trial of Fridge-Stable RNA Vaccine in Australia(2 posts)→
More from Research
- Researcher finds many eval harness functions exist only to patch dataset flaws — remilouf · 2026-10-11
- Bo Wang joins SF Tech Week 'Models to Medicine' panel on virtual cells and Xaira — BoWang87 · 2026-10-11
- AI on track to solve 1,000+ math problems in a month, a 100x jump in 2 months — Dr_Singularity · 2026-10-11
- "The product of math is proofs": a case for vibe mathing everything with AI — cgarciae88 · 2026-10-11
- OpenAI drops 372 math proofs, and mathematicians are grieving — genmon · 2026-10-11
- Was Claude's gibberish fixed by capping KL divergence in RL? One theory — burny_tech · 2026-10-11